Skip to main content

Table 2 Percentage risk reduction (95% CI) for a first moderate/severe exacerbation

From: Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis

 

UMEC/VI vs PBO

UMEC vs PBO

VI vs PBO

UMEC/VI vs UMEC

UMEC/VI vs VI

Patient group/subgroup

 ITT population (N = 3021)

58 (40, 71)

p < 0.001

44 (22, 60)

p < 0.001

39 (15, 56)

p = 0.003

24 (−9, 48)

p = 0.136

31 (2, 52)

p = 0.041

Patient subgroups

 Maintenance-naïve (n = 984)

62 (15, 83)

p = 0.018

22 (−55, 61)

p = 0.475

4 (−82, 49)

p = 0.904

51 (−8, 77)

p = 0.076

60 (16, 81)

p = 0.016

 On maintenance (n = 2037)

56 (35, 71)

p < 0.001

50 (27, 66)

p < 0.001

48 (24, 65)

p < 0.001

12 (−33, 42)

p = 0.540

16 (−27, 45)

p = 0.408

 ICS-free (n = 1543)

62 (30, 80)

p = 0.002

41 (−3, 66)

p = 0.063

15 (−41, 49)

p = 0.520

36 (−20, 66)

p = 0.166

55 (19, 75)

p = 0.008

 ICS-treated (n = 1478)

55 (30, 71)

p < 0.001

46 (19, 65)

p = 0.003

51 (25, 68)

p = 0.001

15 (−33, 46)

p = 0.470

7 (−48, 42)

p = 0.753

 Low rescue use (n = 1488)

71 (43, 85)

p < 0.001

51 (12, 72)

p = 0.018

32 (−16, 61)

p = 0.153

41 (−18, 70)

p = 0.135

57 (17, 78)

p = 0.012

 High rescue use (n = 1490)

49 (22, 67)

p = 0.002

43 (13, 62)

p = 0.009

45 (15, 64)

p = 0.006

12 (−38, 44)

p = 0.580

9 (−44, 42)

p = 0.699

  1. Risk of a first moderate/severe exacerbation was assessed using a Cox proportional hazards model for all medication subgroups separately, with covariates for study, treatment, smoking status at screening and center group. Bold values indicate statistical significance (p < 0.05)
  2. Low rescue use: < 3.6 puffs/day; high rescue use: ≥ 3.6 puffs/day
  3. CI confidence interval, ICS inhaled corticosteroid, ITT intent-to-treat, LS least squares, PBO placebo, UMEC umeclidinium, VI vilanterol
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us